Hospital Universitario de Basurto
Hospital Universitario de Basurto
Bilbao, Spain7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05708235 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | Bone Diseases, Metabolic, Femoral Fractures, Hip Injuries, Leg Injuries, Nutritional and Metabolic Diseases, bone disorder, bone fracture, hip fracture, injury, metabolic disease, musculoskeletal system disorder, osteoporosis | Recruiting | Not applicable | 2026-05-13 | NCT04796350 | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-29 | NCT06172127 | |
| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-03-27 | NCT07371585 | |
| Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies | Invasive Breast Cancer Early Stages | Recruiting | Not stated | 2025-05-14 | NCT03390894 | |
| POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric adenocarcinoma, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Not stated | 2025-01-24 | NCT06790238 |